Peptide therapy for healing and longevity: What the new US policy means for India
Source · The Indian Express
TLDR
The Indian Express reports that US Health Secretary Robert F. Kennedy Jr. announced a draft policy easing compounding access to six experimental peptides under specified conditions. None has FDA approval, and an Indian endocrinologist warns that US enforcement discretion should not be mistaken for medical validation or regulatory approval in India.
- 01The proposal covers BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax; multi-peptide mixtures would not be covered.
- 02The article reports limited human evidence for advertised healing, metabolic and longevity benefits.
- 03Dr Saptarshi Bhattacharya warns that sellers in India could misrepresent US regulatory relaxation as proof of safety or effectiveness.
Why it matters Editorial
The report highlights the distinction between expanded access to experimental peptides and regulatory approval supported by evidence of safety and effectiveness.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
Investing.com Canada